Published 23 hours ago • loading... • Updated 22 hours ago
Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity
China’s National Medical Products Administration accepted Harbour BioMed’s IND application for LET003, the company’s first AI-enabled drug candidate for overweight or obesity treatment.
LET003 is a dual ACVR2A/ACVR2B-blocking monoclonal antibody developed using Harbour BioMed’s Hu-mAtrIx™ AI platform.
In preclinical studies, Harbour BioMed reported that LET003 showed better pharmacokinetic characteristics than several competitor molecules.
Harbour BioMed reported that LET003 enhanced fat reduction when combined with semaglutide while preserving lean mass, and that a lower dose promoted lean mass similarly to a higher dose of bimagrumab.